SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001628280-24-019453
Filing Date
2024-05-01
Accepted
2024-05-01 06:38:17
Documents
19
Period of Report
2024-05-01
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K gthx-20240501.htm   iXBRL 8-K 28481
2 EX-99.1 pressrelease-1q24financi.htm EX-99.1 15817
6 pressrelease-1q24financi001.jpg GRAPHIC 175172
7 pressrelease-1q24financi002.jpg GRAPHIC 249163
8 pressrelease-1q24financi003.jpg GRAPHIC 211250
9 pressrelease-1q24financi004.jpg GRAPHIC 251827
10 pressrelease-1q24financi005.jpg GRAPHIC 125354
  Complete submission text file 0001628280-24-019453.txt   1574255

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT gthx-20240501.xsd EX-101.SCH 1922
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT gthx-20240501_lab.xml EX-101.LAB 22548
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT gthx-20240501_pre.xml EX-101.PRE 13060
22 EXTRACTED XBRL INSTANCE DOCUMENT gthx-20240501_htm.xml XML 2833
Mailing Address 700 PARK OFFICES DRIVE SUITE 200 RESEARCH TRIANGLE PARK NC 27709
Business Address 700 PARK OFFICES DRIVE SUITE 200 RESEARCH TRIANGLE PARK NC 27709 919-213-9835
G1 Therapeutics, Inc. (Filer) CIK: 0001560241 (see all company filings)

IRS No.: 263648180 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38096 | Film No.: 24899972
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)